{
  "docId": "019de076-4b6e-745e-b621-2097373bdc12",
  "docSlug": "454a033dcd11e0912fc4b281c3c86d65",
  "documentTitle": "Innoviva | Results Presentation Deck | 7 slides",
  "authorId": "innoviva",
  "authorName": "Innoviva",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 7,
  "prevPage": 6,
  "nextPage": null,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 26,
  "notes": "The slide uses a split-layout with key takeaways on the left and supporting clinical data tables on the right.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4b6e-745e-b621-2097373bdc12/7",
  "deckHref": "/decks/019de076-4b6e-745e-b621-2097373bdc12",
  "deckJsonHref": "/decks/019de076-4b6e-745e-b621-2097373bdc12.json",
  "deckAnchorHref": "/decks/019de076-4b6e-745e-b621-2097373bdc12#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.08,
        "y": 0.25
      },
      "kind": "list",
      "text": "In this study, zoliflodacin was safe and generally well-tolerated. The overall rate of adverse events was comparable between the two arms. The majority of adverse events were mild to moderate. There were no discontinuations reported due to adverse events, serious adverse events, or deaths.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1e88dc2e-f602-4bad-9eb7-1cc4c372968e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.04,
        "y": 0.93
      },
      "kind": "subtitle",
      "text": "Abbreviations: TEAE – Treatment emergent adverse event; SAE – Serious adverse event; CRO-AZI – ceftriaxone and azithromycin",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b24802db-7b09-4222-a1f4-0f4a1b5f3774",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.42,
        "x": 0.54,
        "y": 0.0018
      },
      "kind": "table",
      "text": "Safety data table comparing Zoliflodacin (N=619) and CRO-AZI (N=308) across various TEAE categories and specific events.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4accab7a-2491-4226-bb35-06f99fdffe01",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Favorable safety and tolerability profile in this study",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4fc1343c-3ec6-455e-83c4-2e4a987efad5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Data Story Arc",
      "slug": "data-story-arc",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "70f9515d-7232-40c6-a6d2-e8d3e90e1236",
      "evidence": "table/data: Safety data table comparing Zoliflodacin (N=619) and CRO-AZI (N=308) across various TEAE categories and specific events.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 7,
      "from": 7,
      "beatId": "ed7992a7-59f2-4e41-9ca1-562e5b4b2bc7",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "Favorable safety and tolerability profile",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 7,
      "from": 2,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "cc60ccb3-7bfb-482b-bd2f-71df33588aa9",
      "evidence": "Implication of antibiotic resistance and need for new treatments",
      "position": 0,
      "objective": "What are the consequences of not adopting Zoliflodacin?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}